1. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology
2. Braun M, Cawello W, Horstmann R. 2005a. Lack of pharmacokinetic interactions between the dopamine agonist rotigotine and levodopa/ carbidopa [abstract]. 16th International Congress on Parkinson's Disease and Related Disorders; 2005 June 5-9. Berlin. PS002/03
3. Braun M, Cawello W, Poole K, Horstmann R. 2005b. Steady-state pharmacokinetics of rotigotine in patients with early-stage Parkinson's disease [abstract]. 9th Congress of the European Federation of Neurological Societies. 2005 Sep 17-20; Athens. P1245.
4. Cawello W, Braun M, Horstmann R. 2005. Pharmacokinetics of transdermal rotigotine in subjects with impaired renal function [abstract]. 34th Annual Meeting of the American College of Clinical Pharmacology. 2005 Sep 11-13; Rockville, MD, USA. 102.
5. The antiparkinsonian actions and pharmacokinetics of transdermal (+)-4-Propyl-9-hydroxynaphthoxazine (+ PHNO): Preliminary results